By Professor Jeff Holst

Conference Abstracts

Savary C; Persson ML; Jackson ER; Duchatel RJ; Vo T; Findlay IJ; Douglas AM; Bramberger L; de la Nava D; Thomas BC; McEwen HP; Beitaki TS; de la Fuente LR; Colino-Sanguino Y; Mora FV; Larsen MR; Faridi P; Holst J; Mayall J; Kline CN; Franson AT; Venneti S; Hondermarck H; Horvat J; Nixon B; Cartaxo R; Nazarian J; Hulleman E; Mueller S; Vitanza NA; Koschmann C; Alonso MM; Carvalheiro TF; van der Lugt J; Dun MD, 2025, 'DDDR-38. Leveraging the immunomodulatory effects of dordaviprone (ONC201) to induce long-term survival response in diffuse midline glioma patients and models', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v171 - v171, http://dx.doi.org/10.1093/neuonc/noaf201.0675

Chung S; Holst J; Teng C; Cooper A; Wei J; Koh E-S; Yeo N; Sim H-W; Killen AJ; Gayaman R; Lynch S; Mandala A; Murray C; Joshi S; Mcdonald K; Ashley D; Desjardins A; Sampson J; Archer G; Lemech C; Hovey E, 2025, 'INTERROGATE-GBM Phase I trial: Immunotherapy peptide vaccine targeting cytomegalovirus (CMV) antigens in glioblastoma', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 27, pp. v425 - v425, http://dx.doi.org/10.1093/neuonc/noaf201.1679

Persson ML; Jackson ER; Duchatel RJ; de la Nava D; Thomas BC; Savary C; McEwen HP; Beitaki TS; Kearney PS; Findlay IJ; Douglas AM; Larsen MR; Faridi P; Holst J; Mayall J; Hondermarck H; Horvat J; Nixon B; Cartaxo RT; Nazarian J; Hulleman E; Mueller S; Vitanza NA; Koshmann C; Alonso MM; Carvalheiro T; van der Lugt J; Dun MD, 2024, 'DIPG-36. DRD2 ANTAGONISM RESCUES IMMUNE-TUMOR SURVEILLANCE, WARMING THE TUMOR IMMUNE MICROENVIRONMENT OF DIFFUSE MIDLINE GLIOMA MODELS', in Neuro-Oncology, Oxford University Press (OUP), Vol. 26, http://dx.doi.org/10.1093/neuonc/noae064.089

Wahi K; Freidman N; Wang Q; Guan YF; Holst J, 2023, 'Macropinocytosis mediates metabolic resistance to loss of glutamine transport in triple-negative breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, Vol. 84, presented at AACR Special Conference on Cancer Research - Advances in Breast Cancer Research, CA, San Diego, 19 October 2023 - 22 October 2023, http://dx.doi.org/10.1158/1538-7445.ADVBC23-A036

Zhao X; Zhang YY; Xu L; La T; Feng YC; Tang HJ; Xu R; Narayana VK; De Souza DP; Quek L-E; Holst J; Thorne RF; Baker M; Liu T; Jin L; Zhang XD, 2023, 'Disruption of nucleotide homeostasis confers cancer cell susceptibility to oxidative phosphorylation inhibition independently of energy depletion', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, FL, Orlando, Vol. 83, presented at 114th Annual Meeting of the American-Association-for-Cancer-Research (AACR), FL, Orlando, 14 April 2023 - 19 April 2023, http://dx.doi.org/10.1158/1538-7445.AM2023-3687

Persson M; Jackson E; Duchatel R; Bramberger L; McEwen H; Kearney P; Findlay I; Douglas A; Kobbe B; Wagener R; Larsen M; Faridi P; Holst J; Mayall J; Gedye C; Hondermarck H; Horvat J; Nixon B; Cartaxo R; Koschmann C; Valdes-Mora F; Ortega DG; Nazarian J; Alonso MM; Hulleman E; Van der Lugt J; Vitanza N; Mueller S; Dun M, 2022, 'TMIC-06. ANTAGONISM OF DRD2 USING ONC201 INCREASED EXPRESSION OF ANTIGEN PRESENTATION PATHWAY PROTEINS IN DIFFUSE MIDLINE GLIOMA, RECRUITING TUMOR INFILTRATING LYMPHOCYTES IN VIVO', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. vii272 - vii272, http://dx.doi.org/10.1093/neuonc/noac209.1050

Mandigo AC; McNair C; Ku K; Pang A; Guan YF; Holst J; Brown M; Kelly WK; Knudsen KE, 2020, 'Molecular underpinnings of RB status as a biomarker of poor outcome in advanced prostate cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 189 - 189, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.189

Mandigo AC; McNair C; Ku K; Pang A; Guan YF; Holst J; Brown M; Kelly WK; Knudsen KE, 2020, 'Molecular underpinnings of RB status as a biomarker of poor outcome in advanced prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020

van Geldermalsen M; Quek L-E; Turner N; Balaban S; Hoy A; Pang A; Guan YF; Wahi K; Wang Q; Holst J, 2019, 'Vulnerabilities in glutamine metabolism define triple-negative from Luminal A breast cancer subsets', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P3-02-09

Akerman A; Sharbeen G; Holst J; Youkhana J; McCarroll J; Goldstein D; Erkan M; Phillips P, 2018, 'Targeting a solute carrier to metabolically reprogram tumour-promoting stromal cells in pancreatic cancer', in Pancreatology, Elsevier BV, Vol. 18, pp. S156 - S156, http://dx.doi.org/10.1016/j.pan.2018.05.419

van Geldermalsen M; Wang Q; Bailey CG; Feng Y; Nagarajah R; Marshall A; Thoeng A; O'Toole S; Rasko JEJ; Holst J, 2015, 'Targeting the ASCT2 glutamine uptake and metabolism pathway in triple-negative breast cancer', in Annals of Oncology, Vol. 26, pp. iii31, http://dx.doi.org/10.1093/annonc/mdv121.04

Colas C; Grewer C; Gameiro A; Albers T; Singh K; Otte NJ; Shere H; Massimiliano B; Holst J; Schlessinger A, 2015, 'Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening', in BIOPHYSICAL JOURNAL, CELL PRESS, Vol. 108, pp. 54A - 54A, http://dx.doi.org/10.1016/j.bpj.2014.11.329

Wang Q; Bailey CG; Ng C; Tiffen J; Thoeng A; Minnas V; Lehman ML; Hendy SC; Buchanan G; Nelson CC; Rasko JEJ; Holst J, 2012, 'Androgen receptor and nutrient signaling pathways coordinate increased amino acid transport in prostate cancer progression', in BMC proceedings, Vol. 6, pp. P23 - P23, http://dx.doi.org/10.1186/1753-6561-6-s3-p23

Ardjmand A; Bock CED; Molloy TJ; Bone SM; Johnstone D; Campbell DM; Shipman KL; Yeadon TM; Holst J; Spanevello MD; Catchpoole DR; Lincz LF; Boyd AW; Burns GF; Thorne RF, 2011, 'Altered expression of Fat1 cadherin, a novel tumor marker for acute lymphoblastic leukemia', in Clinical Biochemistry, Elsevier, Vol. 44, pp. s71, http://dx.doi.org/10.1016/j.clinbiochem.2011.08.154

Tiffen JC; Bailey CG; Ng C; Watson SL; Loukinov DI; Lobanenkov VV; Holst J; Rasko JEJ, 2010, 'BORIS and its paralogue CTCF exhibit similar biological functions', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, NORWAY, Oslo, Vol. 8, pp. 176 - 177, presented at 21st Meeting of the European-Association-for-Cancer-Research, NORWAY, Oslo, 26 June 2010 - 29 June 2010, http://dx.doi.org/10.1016/S1359-6349(10)71497-X

Back to profile page